XRHealth Acquires PursueCare for Connected Addiction Care

PursueCare's sellers have a continuing financial stake in how the business sells over the next 24 months. Performance warrants described in an XRHealth securities filing tie part of their potential upside to a sales milestone, putting an operating incentive inside an acquisition that brings addiction clinicians and prescription software under a broader healthcare owner.

XRHealth announced its acquisition of PursueCare on November 9, 2026. The transaction adds virtual addiction-treatment services and RESET and RESET-O prescription digital therapeutics to the Massachusetts company's immersive-care business. For referring providers and health plans, the combination raises a practical question about how those services will work together around a patient's continuing treatment.

The companies describe plans to connect smartphone-based care with immersive peer support. Their announcement establishes the transaction and its intended direction, while the public financial record supplies a more specific account of equity consideration. Neither source provides results from a fully integrated care model.

What XRHealth acquired, and what the filing reveals

The acquisition announcement includes PursueCare's multidisciplinary clinical operation as well as its prescription digital therapeutics. That gives XRHealth responsibility for more than a product catalog: a care-delivery organization also carries relationships with patients, clinicians and referral sources. How those relationships continue will matter to the businesses already depending on them.

An XRHealth Form D reports $16.253M in common-stock consideration associated with the acquisition of PursueCare LLC and Harvest Bio LLC. The filing identifies 1,146,849 common shares at $14.1719 per share and performance warrants covering up to 705,622 additional shares, contingent on a 24-month sales milestone. Those disclosures describe acquisition securities; treating the reported amount as fresh operating cash would misread the transaction.

The public announcement leaves total purchase economics unspecified. The filing's October 22 first-sale date also should not be substituted for a confirmed legal closing date, and the reviewed materials do not establish a deal-specific regulatory timetable. The useful financial conclusion is narrower: sellers received equity exposure, with a further incentive connected to sales over time.

PursueCare had already brought software into clinical care

PursueCare entered this transaction with a history of buying therapeutic technology itself. In a December 2023 announcement, the Middletown, Connecticut company disclosed a $20M Series B led by T.Rx Capital and Yamaha Motor Ventures, with Seyen Capital and OCA Ventures participating. It also announced the acquisition of RESET and RESET-O, originally developed by Pear Therapeutics.

That earlier decision gives the XRHealth acquisition a useful commercial lineage. Prescription software had moved into a company delivering treatment, where clinicians could decide how it belonged in a patient's care. The next owner is expanding the range of technologies and services around that arrangement, taking on the work of making them useful together.

Nicholas Mercadante remains identified as founder and CEO on PursueCare's current leadership page, which lists Steven Varjabedian as CTO. The combination places clinical and technology leadership inside the same integration assignment, although the reviewed sources do not describe a post-acquisition reporting structure. The relevant customer group includes organizations making referrals or paying for care, alongside the patients using it.

PursueCare's existing service reaches people through a smartphone and combines several kinds of professional support. A referring organization therefore has a reason to ask about care-team continuity, escalation and follow-up alongside any newly available therapeutic tool. The answer will shape whether a broader offering makes that referral easier to manage.

Prescription software carries a defined clinical job

RESET and RESET-O serve different indicated populations. The FDA's RESET decision summary describes adjunctive prescription treatment for specified adults receiving clinician-supervised outpatient substance-use care, with exclusions including people whose primary substance of abuse is opioids. It should not be described as a general-purpose treatment for every addiction.

The FDA documentation for RESET-O specifies support for retention in outpatient opioid-use-disorder treatment alongside buprenorphine and contingency management under clinician supervision. Both products belong within a course of care. Their regulatory status cannot establish that every service or future combination offered by their new owner has the same authorization or evidence.

PursueCare's digital-therapeutics description explains the practical components: cognitive behavioral therapy, exercises that reinforce learned skills, and contingency management that rewards targeted treatment behaviors. Clinicians retain a role in determining suitability and using the software within treatment. Ownership can put those components closer to other services, but the clinical decisions remain specific to the person receiving care.

For healthcare buyers, this creates a detailed evaluation rather than an automatic expansion of coverage. A health plan or referring provider needs to understand which program is available, who supervises it and how it connects to existing treatment. The acquisition gives those conversations a larger organizational setting while leaving the product-specific questions intact.

The connection XRHealth wants to build

Eran Orr, XRHealth's founder and CEO, describes a business connecting therapeutic technologies with clinical services. The company's current platform description spans immersive devices, mobile programs, wearables and clinician-guided care. PursueCare adds an addiction-treatment organization with its own established service relationships to that broader ambition.

One announced connection involves avatar-based VR support groups, which could give PursueCare patients another setting for peer participation with greater privacy. That is a company integration plan, and its usefulness will depend on the experience around it: how someone enters a group, how the service relates to ongoing treatment and how the care team stays informed. The acquisition announcement does not answer all those operating questions.

The commercial opportunity sits in offering a referring institution a more coherent set of services around ongoing care. Greater breadth also means more relationships to coordinate, including the people prescribing software and those helping a patient stay connected to treatment. Healthcare operators evaluating XRHealth can now ask how those responsibilities will be shared across the combined organization.

Meanwhile, PursueCare's existing care teams continue to represent the human part of the acquisition's promise. As the sellers' sales milestone approaches, the business will be expanding around patients whose treatment still involves appointments, prescriptions and ordinary practical obstacles. The integration work follows them into the next referral and the next conversation with a clinician.